Volume 86 Issue 32 | p. 21 | Concentrates
Issue Date: August 11, 2008

Pharmacopeia And Acadia Cut Workforce

Department: Business

Two drug discovery and development companies have revealed restructurings and workforce reductions timed to second-quarter earnings announcements. Acadia Pharmaceuticals will focus on its Phase III trials of pimavanserin for Parkinson's disease psychosis and two compounds funded by partner Allergan. It plans to reduce its workforce by 50%, to 65 employees. Pharmacopeia will terminate 40% of its workforce, in addition to a 15% reduction in May 2008. The company, which had 169 employees at the end of 2007, plans to begin Phase II trials on PS433540, a small-molecule drug for diabetic nephropathy.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment